RxDoctor Payments Data

Rizwan Moinuddin, DO

Nephrology · Melrose Park, ILNPI 1275568578

Payments from drug & device makers

$23,104in general payments, 2019–2025

Across 165 payments — averaging $140.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$10K
  • Outset Medical Inc$8K
  • GSK$899
  • Mallinckrodt Hospital Products Inc.$746
  • Travere Therapeutics, Inc.$627
  • Bayer$434
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$1120%
  • Speaking & faculty fees$13,38058%
  • Travel & lodging$2,31110%
  • Food & beverage$7,23231%
  • Education$200%
  • Entertainment$490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,104 in reported general payments places this provider in the 85th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$310,248
Medicare patients
503
Services billed
2,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FilspariSparsentan15$162,147
FarxigaDapagliflozin Propanediol122$113,079
JardianceEmpagliflozin59$78,400
VelphoroSucroferric Oxyhydroxide21$44,051
AuryxiaFerric Citrate16$29,745
KerendiaFinerenone20$21,800
Sevelamer Carbonate77$19,377
Lanthanum Carbonate11$11,012
LokelmaSodium Zirconium Cyclosilicate12$8,927
Bumetanide105$3,520
Midodrine Hcl38$2,547
Hydralazine Hcl71$1,686
Calcium Acetate19$1,644
Nifedipine ErNifedipine29$1,537
Torsemide73$1,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Travere Therapeutics, Inc.Filspari$627$162,14715 claims
AstraZenecaFarxiga, Lokelma$391$122,007134 claims
Fresenius USA Marketing, Inc.Velphoro$414$44,05121 claims
Akebia Therapeutics IncAuryxia$227$29,74516 claims
BayerKerendia$434$21,80020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 524 nephrology providers in Illinois.

Other nephrology in Melrose Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →